QR Code

How to Simplify the Evaluation of Newly Introduced Chemotherapeutic Interventions in Myeloma

When the bortezomib [PS341], adriamycin and dexamethasone (PAD) regimen was first evaluated, the response rate in untreated patients was much superior to that elicited by conventional chemotherapeutic agents. We demonstrated the efficacy of PAD in relapsed or refractory patients by comparing the res...

Whakaahuatanga katoa

I tiakina i:
Ngā kaituhi matua: Treen Carson Michael Morris, Mary B. Drake, Paul J. Kettle, Tracey McGuigan, Maeve Leahy, Michael O’Dwyer, Helen Enright, Tanya O’Shea, Rakesh Popat, Heather E. Oakervee, Kwee Yong, Jamie D. Cavenagh, David A. Cairns, Alberto Alvarez-Iglesias, Gordon Cook
Hōputu: Artigo
Reo:Inglês
I whakaputaina: SAABRON PRESS 2021-02-01
Rangatū:Clinical Hematology International
Ngā marau:
Myeloma
relapse
bortezomib
adriamycin
dexamethasone
response
Urunga tuihono:https://www.atlantis-press.com/article/125952406/view
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite